Clinical trial
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
NCT00346255 · ImmunoGen, Inc., Industry · Completed
Key facts
| NCT number | NCT00346255 |
|---|---|
| Title | BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma |
| Official title | A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma |
| Acronym | IMGN901 |
| Lead sponsor | ImmunoGen, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | BB-10901 |
| Enrollment | 37 |
| Start date | Apr 1, 2005 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Jun 29, 2006 |
| Last update posted | Apr 23, 2013 |
| Countries | Argentina, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: